The PCSK9 decade
نویسندگان
چکیده
منابع مشابه
The PCSK9 decade.
PCSK9 proprotein convertase subtilisin/kexin type (PCSK9) is a crucial protein in LDL cholesterol (LDL-C) metabolism by virtue of its pivotal role in the degradation of the LDL receptor. In recent years, both in vitro and in vivo studies have greatly supplemented our understanding of the (patho)physiological role of PCSK9 in human biology. In the current review, we summarize studies published o...
متن کاملPCSK9 locus influence circulating PCSK9 levels
PCSK9 is a circulating protein, synthesized predominantly in the liver, involved in the regulation of the plasma low-density lipoprotein (LDL)–cholesterol concentration and associated with susceptibility to coronary heart disease (CHD). Proprotein convertase subtilisin/kexin type 9 (PCSK9) shortens the half-life of the LDL-receptor (LDLR), a process independent of its catalytic activity. Human ...
متن کاملThe mystery of PCSK9.
Many of the most important breakthroughs in science do not come from hypothesis-driven experiments. Apart from serendipity, genetics is perhaps our best route to discoveries that elude our intuition. Genetics establishes a relationship between a gene and a phenotype, but does not necessarily provide mechanistic information. The emerging story of PCSK9 (originally called Narc-1) provides a case ...
متن کاملPCSK9 Inhibitors
Alirocumab and evolocumab are monoclonal antibodies that block proprotein convertase subtilisin/kexin type 9 (PCSK9), a circulating protein that degrades low-density lipoprotein (LDL) receptors. These therapies increase LDL receptors on the cell surface and reduce plasma LDL cholesterol. Both therapies are approved to lower LDL cholesterol, a causative agent for atherosclerotic cardiovascular d...
متن کاملHealthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9.
BACKGROUND We measured plasma PCSK9 concentrations in healthy men with a PCSK9 (proprotein convertase subtilisin/kexin type 9) loss-of-function variant (p.R46L), in statin-treated patients with a clinical diagnosis of familial hypercholesterolemia (FH) and carrying a PCSK9 gain-of-function mutation (p.D374Y), and in statin-treated patients with FH due to different genetic causes. METHODS PCSK...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Lipid Research
سال: 2012
ISSN: 0022-2275
DOI: 10.1194/jlr.r026658